FDA approves Optimer's Dificid to treat C. difficile infection

05/30/2011 | Reuters · New York Times (tiered subscription model), The

The FDA approved Optimer Pharmaceuticals' antibiotic Dificid, or fidaxomicin, for treating diarrhea caused by Clostridium difficile. Dificid proved more effective than ViroPharma's vancomycin, a standard antibacterial drug, in sustaining patient response during clinical trials, the agency said.

View Full Article in:

Reuters · New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ